Skip to content
zynerba logo
  • Investors
    • IR Information
    • Stock Information
    • Press Releases
    • Events & Webcasts
    • Presentations
    • Enhanced SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Investor FAQs
    • IRS Form 8937
    • Investor Contacts
  • News
    • Press Releases
    • Events
  • Publications
    • Manuscripts and Presentations
  • Careers
  • LinkedIn
  • Twitter
  • Our Focus
    • Why Rare?
    • Why Neuropsychiatric Disorders?
    • Why Cannabinoids?
    • Why pharmaceutical manufacturing?
  • Our Pipeline
    • ZygelTM
    • Early Access to Medicine
  • Clinical Trials
  • Our Team
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Patient Resources
    • FXS
    • ASD
    • 22q

Zynerba Press Releases

2 Apr 19 Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

11 Mar 19 Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights

7 Mar 19 Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygelâ„¢ in Autism Spectrum Disorder

26 Feb 19 Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol

20 Feb 19 Zynerba Pharmaceuticals Appoints Pamela Stephenson to Board of Directors

5 Feb 19 Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference

17 Dec 18 Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications

12 Dec 18 Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002

20 Nov 18 Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference

8 Nov 18 Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

Page 11 of 20 | « First‹ Previous7 8 9 10 11 12 13 14 15 Next ›Last »

    This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.

    • Privacy Policy
    • Terms of Use
    • Cookie Notice
    • Accessibility Statement
    • Contact Us

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved.

    zynerba inverted logo

    80 W. Lancaster Avenue, Suite 300
    Devon, PA 19333
    484.581.7505